23 Participants Needed

Onvansertib + FOLFIRI + Bevacizumab for Colorectal Cancer

Recruiting at 45 trial locations
VK
NS
Overseen ByNancy Sherman
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Prior Safety DataThis treatment has passed at least one previous human trial
Breakthrough TherapyThis drug has been fast-tracked for approval by the FDA given its high promise

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial is testing a new drug called onvansertib combined with standard chemotherapy and bevacizumab for colorectal cancer patients with specific gene mutations who didn't respond to earlier treatment. The new drug aims to block cancer cell growth, making the existing chemotherapy work better. Bevacizumab is used in combination with chemotherapy for treating advanced colorectal cancer.

Will I have to stop taking my current medications?

The trial does not specify if you need to stop taking your current medications, but you must not use certain medications that affect heart rhythm or specific enzymes. If you're on these, you may need to switch to alternatives before starting the trial.

What is the safety profile of the combination treatment Onvansertib + FOLFIRI + Bevacizumab for colorectal cancer?

Bevacizumab, when combined with chemotherapy like FOLFIRI, is generally safe but can cause side effects such as high blood pressure, bleeding, and blood clots, which are usually mild to moderate and manageable. The combination has been studied primarily in metastatic colorectal cancer, showing that while it can increase some adverse events, these are often outweighed by the benefits in survival.12345

What makes the drug combination of Onvansertib, FOLFIRI, and Bevacizumab unique for colorectal cancer?

This treatment is unique because it combines Onvansertib, a newer drug that targets specific cancer cell processes, with the established FOLFIRI chemotherapy regimen and Bevacizumab, which helps prevent the growth of blood vessels that feed tumors. This combination aims to enhance the effectiveness of treatment for colorectal cancer by attacking the cancer in multiple ways.26789

What data supports the effectiveness of the drug Onvansertib + FOLFIRI + Bevacizumab for colorectal cancer?

Research shows that adding bevacizumab to chemotherapy regimens like FOLFIRI improves survival rates in patients with metastatic colorectal cancer. Additionally, studies have demonstrated that bevacizumab enhances the effectiveness of various chemotherapy combinations, suggesting potential benefits when used with Onvansertib.2691011

Are You a Good Fit for This Trial?

Adults with metastatic colorectal cancer that has progressed after oxaliplatin/fluoropyrimidine-based treatment. They must have KRAS or NRAS mutations, measurable disease via CT/MRI, and good organ function. Not eligible if they've had irinotecan before, brain metastasis, GI absorption issues, certain heart conditions or severe allergies to trial drugs.

Inclusion Criteria

My doctor agrees FOLFIRI therapy is suitable for me.
My cancer has a KRAS or NRAS mutation as confirmed by a certified lab.
My cancer has worsened despite treatment with specific chemotherapy drugs.
See 9 more

Exclusion Criteria

My cancer has specific genetic mutations (KRAS, NRAS, BRAF-V600) or is MSI-H/dMMR.
I have had more than one chemotherapy treatment for cancer that has spread.
I have not had major surgery in the last 6 weeks.
See 12 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive Onvansertib in combination with FOLFIRI and Bevacizumab in 28-day cycles

Up to approximately 1 year
Days 1 to 5 and 15 to 19 for Onvansertib; Days 1 and 15 for SOC in each 28-day cycle

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

  • Bevacizumab
  • FOLFIRI
  • Onvansertib
Trial Overview The trial is testing two doses of Onvansertib in combination with FOLFIRI (irinotecan, fluorouracil [5-FU], leucovorin) and Bevacizumab against just FOLFIRI and Bevacizumab for those who didn't respond well to first-line therapy for their KRAS/NRAS mutated colorectal cancer.
How Is the Trial Designed?
3Treatment groups
Experimental Treatment
Active Control
Group I: Onvansertib 30 mg + Standard of Care (SOC)Experimental Treatment3 Interventions
Group II: Onvansertib 20 mg + Standard of Care (SOC)Experimental Treatment3 Interventions
Group III: Standard of Care (SOC)Active Control2 Interventions

Bevacizumab is already approved in European Union, United States, Japan, Canada for the following indications:

🇪🇺
Approved in European Union as Avastin for:
🇺🇸
Approved in United States as Avastin for:
🇯🇵
Approved in Japan as Avastin for:
🇨🇦
Approved in Canada as Avastin for:

Find a Clinic Near You

Who Is Running the Clinical Trial?

Cardiff Oncology

Lead Sponsor

Trials
12
Recruited
650+

Published Research Related to This Trial

In a phase IV trial involving 209 treatment-naïve patients with metastatic colorectal cancer, the combination of bevacizumab and FOLFIRI resulted in a median progression-free survival (PFS) of 11.1 months and a median overall survival (OS) of 22.2 months, demonstrating its efficacy as a first-line treatment.
The treatment was generally well-tolerated, with most adverse events being mild (grade 1/2), while serious side effects like neutropenia and venous thromboembolic events occurred in over 10% of patients, indicating manageable safety concerns.
Phase IV study of bevacizumab in combination with infusional fluorouracil, leucovorin and irinotecan (FOLFIRI) in first-line metastatic colorectal cancer.Sobrero, A., Ackland, S., Clarke, S., et al.[2022]
The combination of FOLFOXIRI and bevacizumab demonstrated a promising progression-free survival (PFS) rate of 74% at 10 months in patients with unresectable metastatic colorectal cancer, based on a phase 2 study involving 57 patients.
The treatment was found to be safe, with no unexpected adverse events reported, although common serious side effects included neutropenia and hypertension, indicating that while effective, careful monitoring for these side effects is necessary.
Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial.Masi, G., Loupakis, F., Salvatore, L., et al.[2022]
In a meta-analysis of 11 randomized controlled trials involving 3178 patients, the combination of bevacizumab (BEV) with the FOLFOX regimen significantly improved the objective response rate and cancer control rate compared to FOLFOX alone.
However, this combination treatment was associated with a higher incidence of gastrointestinal adverse reactions, indicating a trade-off between increased efficacy and potential side effects.
The efficacy and safety of bevacizumab combined with FOLFOX regimen in the treatment of advanced colorectal cancer: A systematic review and meta-analysis.Zhang, H., You, J., Liu, W., et al.[2023]

Citations

Phase IV study of bevacizumab in combination with infusional fluorouracil, leucovorin and irinotecan (FOLFIRI) in first-line metastatic colorectal cancer. [2022]
Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial. [2022]
The efficacy and safety of bevacizumab combined with FOLFOX regimen in the treatment of advanced colorectal cancer: A systematic review and meta-analysis. [2023]
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. [2022]
A Multicenter Clinical Phase II Study of FOLFOXIRI Plus Bevacizumab as First-line Therapy in Patients With Metastatic Colorectal Cancer: QUATTRO Study. [2022]
Managing patients treated with bevacizumab combination therapy. [2015]
Targeted therapies in the management of colorectal carcinoma: role of bevacizumab. [2021]
AMALTHEA: Prospective, Single-Arm Study of the Hellenic Cooperative Oncology Group (HeCOG) Evaluating Efficacy and Safety of First-Line FOLFIRI + Aflibercept for 6 Months Followed by Aflibercept Maintenance in Patients With Metastatic Colorectal Cancer. [2019]
Efficacy and safety of addition of bevacizumab to FOLFIRI or irinotecan/bolus 5-FU/LV (IFL) in patients with metastatic colorectal cancer: A meta-analysis. [2022]
Efficacy and safety of bevacizumab-based combination regimens in patients with previously untreated metastatic colorectal cancer: final results from a randomised phase II study of bevacizumab plus 5-fluorouracil, leucovorin plus irinotecan versus bevacizumab plus capecitabine plus irinotecan (FNCLCC ACCORD 13/0503 study). [2018]
FOLFIRI plus bevacizumab as second-line therapy in patients with metastatic colorectal cancer after first-line bevacizumab plus oxaliplatin-based therapy: the randomized phase III EAGLE study. [2022]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security